Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-199a-5p AADAT 0.59 0.06748 0.34 0.31218 miRanda -0.11 0.02907 NA
2 hsa-miR-199a-5p ABCA10 0.59 0.06748 -0.56 0.32174 miRanda -0.21 0.01371 NA
3 hsa-miR-199a-5p ABCC3 0.59 0.06748 1.12 0.02241 miRanda -0.16 0.03386 NA
4 hsa-miR-155-5p ABCC4 1.2 0.00086 -1.54 1.0E-5 miRNAWalker2 validate -0.18 0.0001 NA
5 hsa-miR-199a-5p ABCG2 0.59 0.06748 -1.34 0.00067 miRanda -0.16 0.00608 22498306 miR-199a significantly increased the chemosensitivity of ovarian CICs to cisplatin pacitaxel and adriamycin and reduced mRNA expression of the multidrug resistance gene ABCG2 as compared with miR-199a mutant-transfected and untransfected cells
6 hsa-miR-155-5p ACADSB 1.2 0.00086 -1 0.00017 mirMAP -0.27 0 NA
7 hsa-miR-199a-5p ACER2 0.59 0.06748 0.02 0.97526 miRanda -0.26 0.00177 NA
8 hsa-miR-199a-5p ACOT11 0.59 0.06748 0.06 0.86393 mirMAP -0.2 0.0001 NA
9 hsa-miR-155-5p ACTA1 1.2 0.00086 -1.87 0 MirTarget; miRNATAP -0.17 0.00185 NA
10 hsa-miR-145-5p ACVR1B -1.55 0 0.35 0.04863 MirTarget; miRNATAP -0.17 0 NA
11 hsa-miR-199a-5p ACVR1B 0.59 0.06748 0.35 0.04863 PITA; miRanda; miRNATAP -0.13 0 NA
12 hsa-miR-155-5p ACVR2A 1.2 0.00086 -0.44 0.02646 miRNATAP -0.26 0 NA
13 hsa-miR-193b-5p ACVR2A 1.6 0 -0.44 0.02646 MirTarget -0.14 1.0E-5 NA
14 hsa-miR-199a-5p ACVR2A 0.59 0.06748 -0.44 0.02646 PITA; miRanda; miRNATAP -0.1 0.00066 NA
15 hsa-miR-30a-5p ACVR2A -0.88 0.00051 -0.44 0.02646 miRNATAP -0.11 0.00276 NA
16 hsa-miR-199a-5p ACVR2B 0.59 0.06748 0.83 0.00058 PITA; miRNATAP -0.11 0.0019 NA
17 hsa-miR-155-5p ADAM10 1.2 0.00086 0.67 0.00766 miRNAWalker2 validate -0.11 0.00135 NA
18 hsa-miR-193b-5p ADAM22 1.6 0 -1.12 0.02589 MirTarget -0.42 0 NA
19 hsa-miR-148a-5p ADAMTS15 1.16 0.00015 -2.81 0 mirMAP -0.33 0.0006 NA
20 hsa-miR-199a-5p ADAMTS19 0.59 0.06748 -2.99 0 miRanda -0.2 0.03612 NA
21 hsa-miR-148a-5p ADAMTS5 1.16 0.00015 -2.16 0 mirMAP; miRNATAP -0.2 0.00011 NA
22 hsa-miR-193b-5p ADHFE1 1.6 0 -2.28 0 MirTarget -0.33 1.0E-5 NA
23 hsa-miR-199a-5p ADHFE1 0.59 0.06748 -2.28 0 miRanda -0.14 0.04616 NA
24 hsa-miR-199a-5p ADNP 0.59 0.06748 0.23 0.1236 miRanda -0.1 0 NA
25 hsa-miR-155-5p AGL 1.2 0.00086 -0.67 6.0E-5 miRNAWalker2 validate -0.17 0 NA
26 hsa-miR-155-5p AGTR1 1.2 0.00086 -4.49 0 miRNAWalker2 validate; miRTarBase -0.18 0.02184 22525818 MicroRNA-155 miR-155 is one of the micro RNAs miRNA most consistently involved in neoplastic diseases and it is known to repress the angiotensin II type 1 receptor AGTR1; The aim of the present study was to evaluate the expressions of miR-155 and AGTR1 and to clarify the potential efficacy of anti-miR-155 alone and in combination with AGTR1 blocker losartan in endometrial cancers; Expressions of miR-155 and AGTR1 were evaluated using real-time PCR and immunohistochemistry; miR-155 was over-expressed and AGTR1 was underexpressed in endometrial carcinoma tissues; We checked that abolishing the function of miR-155 and AGTR1 by anti-miR-155 or losartan inhibited cell survival of endometrial carcinoma cells respectively and furthermore combined treatment showed synergistic effects; In this study we characterized the expressions of miR-155 and AGTR1 in endometrial tissues; The combined treatment with anti-miR-155 and losartan has a synergistic antiproliferative effect and an improved understanding is required to clarify whether miR-155 and AGTR1 can be used as a novel therapeutic target in endometrial cancer
27 hsa-miR-155-5p AHRR 1.2 0.00086 -1.31 0.00015 MirTarget -0.13 0.00706 NA
28 hsa-miR-199a-5p AIG1 0.59 0.06748 0.22 0.29778 miRanda -0.13 5.0E-5 NA
29 hsa-miR-199a-5p AKAP1 0.59 0.06748 -0.34 0.0302 PITA; miRanda; miRNATAP -0.12 0 NA
30 hsa-miR-193b-5p AKAP13 1.6 0 -1.15 0 mirMAP -0.14 0 NA
31 hsa-miR-199a-5p AKAP7 0.59 0.06748 -1.26 1.0E-5 miRanda -0.13 0.00298 NA
32 hsa-miR-155-5p AKR1C3 1.2 0.00086 -0.32 0.59634 miRNAWalker2 validate -0.28 0.0004 NA
33 hsa-miR-199a-5p ALCAM 0.59 0.06748 -0.73 0.05647 miRanda -0.12 0.02971 NA
34 hsa-miR-155-5p ALDH1A2 1.2 0.00086 -1.89 0.0017 miRNAWalker2 validate -0.42 0 NA
35 hsa-miR-155-5p ALDH5A1 1.2 0.00086 0.21 0.50454 miRNAWalker2 validate -0.19 1.0E-5 NA
36 hsa-miR-148a-5p ALPK3 1.16 0.00015 -1.02 0.00049 mirMAP -0.23 0 NA
37 hsa-miR-155-5p AMIGO2 1.2 0.00086 0.86 0.01664 miRNAWalker2 validate -0.2 3.0E-5 NA
38 hsa-miR-30a-5p AMMECR1 -0.88 0.00051 0.72 0.00063 miRNATAP -0.11 0.00848 NA
39 hsa-miR-145-5p ANGPT2 -1.55 0 0.16 0.56556 MirTarget; miRNATAP -0.17 5.0E-5 24384875; 27570490 miR 145 functions as tumor suppressor and targets two oncogenes ANGPT2 and NEDD9 in renal cell carcinoma; We further validated those miR-145 targets two oncogenes ANGPT2 and NEDD9 in RCC;MiR 145 functions as a tumor suppressor via regulating angiopoietin 2 in pancreatic cancer cells; The direct action of miR-145 on Ang-2 was predicted by TargetScan and confirmed by luciferase report assay; The expression level of miR-145 was significantly lower and the expression levels of Ang-2 mRNA and protein was significantly higher in the more aggressive pancreatic cancer cells MiaPaCa-2 and Panc-1 when compared to that in BxPC3 cells; Overexpression of miR-145 in the BxPC3 MiaPaCa-2 and Panc-1 cells suppressed the cell invasion and colony formation ability and the expression level of Ang-2 protein in MiaPaCa-2 and Panc-1 cells was also suppressed after pre-miR-145 transfection; Intratumoral delivery of miR-145 inhibited the growth of pancreatic cancer xenografts and angiogenesis in vivo and also suppressed the expression level of angiopoietin-2 protein; MiR-145 functions as a tumor suppressor in pancreatic cancer cells by targeting Ang-2 for translation repression and thus suppresses pancreatic cancer cell invasion and growth which suggests that restoring of miR-145 may be a potential therapeutic target for pancreatic cancer
40 hsa-miR-199a-5p ANKAR 0.59 0.06748 -0.59 0.0026 miRanda -0.11 8.0E-5 NA
41 hsa-miR-199a-5p ANKRA2 0.59 0.06748 -0.15 0.35304 miRanda -0.16 0 NA
42 hsa-miR-30a-5p ANKRD17 -0.88 0.00051 -0.09 0.56547 MirTarget; miRNATAP -0.11 0.00034 NA
43 hsa-miR-155-5p ANO5 1.2 0.00086 -3.19 0 MirTarget -0.4 0 NA
44 hsa-miR-199a-5p APOL1 0.59 0.06748 0.83 0.03268 miRanda -0.12 0.04082 NA
45 hsa-miR-155-5p AR 1.2 0.00086 -3.3 0 mirMAP -0.6 0 27035278 MicroRNA 155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2
46 hsa-miR-145-5p ARAP2 -1.55 0 0.68 0.00503 MirTarget -0.14 8.0E-5 NA
47 hsa-miR-155-5p ARFIP1 1.2 0.00086 -0.25 0.05443 miRNAWalker2 validate -0.11 0 NA
48 hsa-miR-155-5p ARGLU1 1.2 0.00086 0.37 0.05354 miRNAWalker2 validate -0.12 0 NA
49 hsa-miR-199a-5p ARHGAP12 0.59 0.06748 0.02 0.92353 PITA; miRanda; miRNATAP -0.13 0 NA
50 hsa-miR-148a-5p ARHGAP29 1.16 0.00015 -0.34 0.31665 MirTarget -0.11 0.04655 NA
51 hsa-miR-155-5p ARHGAP32 1.2 0.00086 0.68 0.00492 mirMAP -0.21 0 NA
52 hsa-miR-30a-5p ARHGAP32 -0.88 0.00051 0.68 0.00492 MirTarget; mirMAP -0.14 0.00265 NA
53 hsa-miR-155-5p ARHGAP5 1.2 0.00086 -0.63 0.00047 mirMAP -0.11 1.0E-5 NA
54 hsa-miR-199a-5p ARHGEF12 0.59 0.06748 -0.64 4.0E-5 PITA; miRNATAP -0.13 0 NA
55 hsa-miR-30a-5p ARID1A -0.88 0.00051 -0.01 0.971 MirTarget; miRNATAP -0.14 0 NA
56 hsa-miR-155-5p ARID2 1.2 0.00086 -0.05 0.73302 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.16 0 27035278 MicroRNA 155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2
57 hsa-miR-199a-5p ARID2 0.59 0.06748 -0.05 0.73302 miRNATAP -0.14 0 NA
58 hsa-miR-148a-5p ARID5B 1.16 0.00015 -1.57 0 mirMAP -0.13 0.00016 NA
59 hsa-miR-199a-5p ARL6IP1 0.59 0.06748 0.96 0 miRanda -0.11 1.0E-5 NA
60 hsa-miR-148a-5p ART4 1.16 0.00015 -1.65 0.00419 mirMAP -0.27 0.00332 NA
61 hsa-miR-199a-5p ASB16 0.59 0.06748 -0.49 0.04139 miRanda -0.14 0.00011 NA
62 hsa-miR-199a-5p ASPH 0.59 0.06748 -0.08 0.7224 miRanda -0.16 1.0E-5 NA
63 hsa-miR-30a-5p ATAD2B -0.88 0.00051 0.21 0.16127 MirTarget; miRNATAP -0.15 0 NA
64 hsa-miR-30a-5p ATF2 -0.88 0.00051 -0.36 0.09137 mirMAP -0.14 0.00044 NA
65 hsa-miR-199a-5p ATP10B 0.59 0.06748 0.42 0.55956 miRanda -0.34 0.00168 NA
66 hsa-miR-199a-5p ATP7A 0.59 0.06748 -0.61 0.00104 MirTarget; miRanda -0.1 0.00018 NA
67 hsa-miR-155-5p ATRNL1 1.2 0.00086 -2.48 0 MirTarget; mirMAP -0.2 0.00476 NA
68 hsa-miR-30a-5p ATRX -0.88 0.00051 -0.65 1.0E-5 miRNAWalker2 validate -0.11 0.00012 NA
69 hsa-miR-145-5p ATXN7L3 -1.55 0 0.52 0 miRNATAP -0.11 0 NA
70 hsa-miR-30a-5p AVL9 -0.88 0.00051 0.51 0.00081 MirTarget; mirMAP; miRNATAP -0.12 2.0E-5 NA
71 hsa-miR-30a-5p B3GNT5 -0.88 0.00051 -0.26 0.35595 MirTarget; miRNATAP -0.11 0.0319 NA
72 hsa-miR-30a-5p BAG4 -0.88 0.00051 0.14 0.55811 mirMAP -0.16 0.00037 NA
73 hsa-miR-30a-5p BAZ1B -0.88 0.00051 0.1 0.35502 miRNAWalker2 validate -0.11 0 NA
74 hsa-miR-199a-5p BAZ2B 0.59 0.06748 -0.74 3.0E-5 miRanda -0.15 0 NA
75 hsa-miR-30a-5p BAZ2B -0.88 0.00051 -0.74 3.0E-5 miRNATAP -0.12 0.00029 NA
76 hsa-miR-199a-5p BCAM 0.59 0.06748 0.13 0.71566 MirTarget; PITA; miRanda; miRNATAP -0.12 0.03278 NA
77 hsa-miR-30a-5p BCL11B -0.88 0.00051 0.59 0.18314 miRNATAP -0.18 0.02944 NA
78 hsa-miR-148a-5p BCL2L2 1.16 0.00015 -1.27 0 mirMAP -0.14 0 NA
79 hsa-miR-155-5p BCL6 1.2 0.00086 -0.56 0.00743 miRNAWalker2 validate; miRTarBase -0.15 0 23169640 We show that Bcl6 is indirectly regulated by miR-155 through Mxd1/Mad1 up-regulation; Interestingly we found that miR-155 directly targets HDAC4 a corepressor partner of BCL6; Meta-analysis of the diffuse large B-cell lymphoma patient microarray data showed that miR-155 expression is inversely correlated with Bcl6 and Hdac4; Hence this study provides a better understanding of how miR-155 causes disruption of the BCL6 transcriptional machinery that leads to up-regulation of the survival and proliferation genes in miR-155-induced leukemias
80 hsa-miR-30a-5p BCL6 -0.88 0.00051 -0.56 0.00743 miRNATAP -0.13 0.00115 23450486 It was also shown that the patients with BCL-6 protein expression had lower expression of miR-30a compared with the negative group
81 hsa-miR-30a-5p BCL9 -0.88 0.00051 0.12 0.4783 miRNATAP -0.15 0 NA
82 hsa-miR-199a-5p BCO2 0.59 0.06748 -2.28 0 miRanda -0.15 0.01078 NA
83 hsa-miR-30a-5p BCOR -0.88 0.00051 -0.51 0.01107 MirTarget; miRNATAP -0.11 0.0054 NA
84 hsa-miR-148a-5p BDNF 1.16 0.00015 -2.91 0 mirMAP -0.14 0.04454 NA
85 hsa-miR-199a-5p BEND3 0.59 0.06748 0.87 0 miRanda; miRNATAP -0.1 0.0002 NA
86 hsa-miR-30a-5p BEND3 -0.88 0.00051 0.87 0 mirMAP; miRNATAP -0.15 2.0E-5 NA
87 hsa-miR-193b-5p BEND7 1.6 0 -0.64 0.19325 mirMAP -0.26 0.00119 NA
88 hsa-miR-199a-5p BHLHE41 0.59 0.06748 -0.07 0.8646 miRanda -0.15 0.01322 NA
89 hsa-miR-30a-5p BNIP3L -0.88 0.00051 -0.6 0.00028 MirTarget; miRNATAP -0.11 0.00032 NA
90 hsa-miR-199a-5p BRAF 0.59 0.06748 -0.04 0.83954 miRanda -0.1 0.00031 NA
91 hsa-miR-155-5p BRD1 1.2 0.00086 -0.2 0.11017 MirTarget -0.12 0 NA
92 hsa-miR-199a-5p BRPF3 0.59 0.06748 0.03 0.87192 miRanda -0.11 0 NA
93 hsa-miR-155-5p BRWD1 1.2 0.00086 -0.16 0.29426 mirMAP -0.16 0 NA
94 hsa-miR-145-5p BRWD3 -1.55 0 0.22 0.35044 miRNATAP -0.18 0 NA
95 hsa-miR-30a-5p BRWD3 -0.88 0.00051 0.22 0.35044 MirTarget; miRNATAP -0.22 0 NA
96 hsa-miR-199a-5p BTBD3 0.59 0.06748 -0.6 0.00457 PITA; miRanda; miRNATAP -0.16 0 NA
97 hsa-miR-199a-5p BTBD7 0.59 0.06748 -0.3 0.03144 miRanda; mirMAP -0.13 0 NA
98 hsa-miR-199a-5p BTBD9 0.59 0.06748 -0.42 0.00155 miRNATAP -0.11 0 NA
99 hsa-miR-199a-5p BTG2 0.59 0.06748 -2.39 0 miRanda -0.13 0.0183 NA
100 hsa-miR-139-5p BUB1 -1.53 0 2.99 0 miRanda -0.25 0 NA
101 hsa-miR-199a-5p C14orf159 0.59 0.06748 -1.4 0 miRNATAP -0.14 9.0E-5 NA
102 hsa-miR-193b-5p C15orf52 1.6 0 -1.18 0.0026 mirMAP -0.15 0.01616 NA
103 hsa-miR-199a-5p C18orf25 0.59 0.06748 -0.18 0.18737 miRNATAP -0.11 0 NA
104 hsa-miR-199a-5p C1QL3 0.59 0.06748 -0.85 0.03353 miRanda; miRNATAP -0.17 0.00415 NA
105 hsa-miR-148a-5p C1orf21 1.16 0.00015 -1.51 0 mirMAP -0.12 0.00081 NA
106 hsa-miR-155-5p C3orf18 1.2 0.00086 -1.41 0 miRNATAP -0.19 0 NA
107 hsa-miR-155-5p C8orf4 1.2 0.00086 -2.46 0 miRNATAP -0.22 0.00031 NA
108 hsa-miR-148a-5p CA12 1.16 0.00015 -0.95 0.06698 MirTarget -0.18 0.02837 NA
109 hsa-miR-199a-5p CA12 0.59 0.06748 -0.95 0.06698 mirMAP -0.17 0.0257 NA
110 hsa-miR-155-5p CAB39L 1.2 0.00086 -1.33 0.00163 miRNAWalker2 validate -0.47 0 NA
111 hsa-miR-155-5p CACNB4 1.2 0.00086 -2.87 0 mirMAP; miRNATAP -0.25 4.0E-5 NA
112 hsa-miR-199a-5p CAPS2 0.59 0.06748 -0.86 0.0062 miRanda -0.12 0.00871 NA
113 hsa-miR-199a-5p CASC2 0.59 0.06748 -0.8 0.00027 miRanda -0.12 0.00025 NA
114 hsa-miR-193b-5p CBFA2T3 1.6 0 -1.56 2.0E-5 mirMAP -0.31 0 NA
115 hsa-miR-155-5p CBR4 1.2 0.00086 -0.14 0.45863 miRNAWalker2 validate -0.22 0 NA
116 hsa-miR-30a-5p CBX2 -0.88 0.00051 2.76 0 miRNATAP -0.27 0.00049 NA
117 hsa-miR-125a-5p CCL5 0.6 0.01023 -0.09 0.86108 miRNAWalker2 validate -0.27 0.0115 NA
118 hsa-miR-33a-5p CCL5 3.8 0 -0.09 0.86108 MirTarget -0.27 1.0E-5 NA
119 hsa-miR-98-5p CCL5 1.11 0 -0.09 0.86108 miRNAWalker2 validate -0.62 0 NA
120 hsa-miR-199a-5p CCNJ 0.59 0.06748 0.28 0.31217 MirTarget; PITA; miRanda; miRNATAP -0.12 0.00545 NA
121 hsa-miR-155-5p CCNT2 1.2 0.00086 0.05 0.80346 MirTarget -0.2 0 NA
122 hsa-miR-30a-5p CCNT2 -0.88 0.00051 0.05 0.80346 MirTarget; mirMAP; miRNATAP -0.14 0.00019 NA
123 hsa-miR-148a-5p CD109 1.16 0.00015 -0.51 0.31559 mirMAP -0.25 0.00143 NA
124 hsa-miR-148a-5p CD44 1.16 0.00015 -0.8 0.04276 mirMAP -0.18 0.00281 23861222 In MHCC97H and MHCC97L cells over-expression of miR-148a blocked the EMT process attenuated the expression of CD90 and CD44 biomarkers for liver cancer stem cells and inhibited their migratory capacity
125 hsa-miR-148a-5p CD93 1.16 0.00015 -1.4 0 mirMAP -0.14 0.00109 NA
126 hsa-miR-30a-5p CDC20 -0.88 0.00051 3.89 0 miRNAWalker2 validate -0.14 0.03688 NA
127 hsa-miR-30a-5p CDCA7 -0.88 0.00051 1.72 0 MirTarget -0.21 0.00085 NA
128 hsa-miR-155-5p CDH6 1.2 0.00086 -0.98 0.00074 miRNAWalker2 validate -0.15 0.00012 NA
129 hsa-miR-30a-5p CDK12 -0.88 0.00051 0.13 0.30721 MirTarget; miRNATAP -0.1 3.0E-5 NA
130 hsa-miR-30a-5p CDK19 -0.88 0.00051 -0.08 0.56132 MirTarget; mirMAP; miRNATAP -0.11 4.0E-5 NA
131 hsa-miR-139-5p CENPF -1.53 0 3.04 0 miRanda -0.3 0 NA
132 hsa-miR-30c-2-3p CENPF -1.67 0 3.04 0 MirTarget -0.2 0.00037 NA
133 hsa-miR-10a-5p CENPO 1.15 0.00372 1.82 0 mirMAP -0.1 8.0E-5 NA
134 hsa-miR-10b-5p CENPO -0.16 0.55501 1.82 0 mirMAP -0.1 0.00753 NA
135 hsa-miR-125a-5p CENPO 0.6 0.01023 1.82 0 mirMAP -0.14 0.0013 NA
136 hsa-miR-199a-5p CEP350 0.59 0.06748 -0.04 0.77047 miRNATAP -0.1 0 NA
137 hsa-miR-30a-5p CEP350 -0.88 0.00051 -0.04 0.77047 MirTarget; miRNATAP -0.11 2.0E-5 NA
138 hsa-miR-145-5p CHAC2 -1.55 0 0.98 2.0E-5 MirTarget -0.11 0.00146 NA
139 hsa-miR-199a-5p CHD1 0.59 0.06748 -0.57 4.0E-5 miRanda -0.15 0 NA
140 hsa-miR-199a-5p CHD7 0.59 0.06748 0.67 0.00044 miRanda -0.11 0.00023 NA
141 hsa-miR-155-5p CHD9 1.2 0.00086 -0.8 1.0E-5 miRNAWalker2 validate -0.11 0 NA
142 hsa-miR-139-5p CHEK1 -1.53 0 1.6 0 miRanda -0.12 0.0025 NA
143 hsa-miR-193b-5p CHRDL1 1.6 0 -6.15 0 MirTarget -0.85 0 NA
144 hsa-miR-145-5p CHRNB2 -1.55 0 0.9 0.02654 MirTarget -0.15 0.0167 NA
145 hsa-miR-155-5p CHST9 1.2 0.00086 -5 0 miRNATAP -0.34 0.00126 NA
146 hsa-miR-30a-5p CIT -0.88 0.00051 2.11 0 miRNATAP -0.18 0.00016 NA
147 hsa-miR-199a-5p CITED2 0.59 0.06748 -0.85 0.00024 miRanda -0.11 0.00171 NA
148 hsa-miR-125a-5p CKS1B 0.6 0.01023 1.72 0 miRanda -0.13 0.00687 NA
149 hsa-miR-199a-5p CLASP2 0.59 0.06748 -0.3 0.02258 miRanda -0.11 0 NA
150 hsa-miR-199a-5p CLCN3 0.59 0.06748 -0.36 0.09942 miRNATAP -0.15 0 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 151 1784 6.836e-20 3.181e-16
2 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 74 740 1.773e-13 4.125e-10
3 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 113 1517 3.138e-11 4.867e-08
4 NEGATIVE REGULATION OF GENE EXPRESSION 111 1493 5.422e-11 6.307e-08
5 HEAD DEVELOPMENT 66 709 9.032e-11 8.406e-08
6 CENTRAL NERVOUS SYSTEM DEVELOPMENT 74 872 4.45e-10 3.451e-07
7 REGULATION OF CELL DIFFERENTIATION 105 1492 4.071e-09 2.706e-06
8 CHROMATIN MODIFICATION 51 539 7.828e-09 4.553e-06
9 POST EMBRYONIC DEVELOPMENT 18 89 9.818e-09 5.076e-06
10 NEUROGENESIS 98 1402 2.016e-08 9.38e-06
11 EMBRYO DEVELOPMENT 70 894 3.651e-08 1.545e-05
12 FOREBRAIN DEVELOPMENT 37 357 9.426e-08 3.655e-05
13 GROWTH 40 410 1.469e-07 5.258e-05
14 CELL DEVELOPMENT 96 1426 1.7e-07 5.652e-05
15 MULTICELLULAR ORGANISM GROWTH 15 76 2.338e-07 7.254e-05
16 ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 56 689 2.715e-07 7.895e-05
17 REGULATION OF NERVOUS SYSTEM DEVELOPMENT 59 750 3.878e-07 0.0001002
18 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 107 1672 3.838e-07 0.0001002
19 NEURON PROJECTION DEVELOPMENT 47 545 4.794e-07 0.0001174
20 REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 30 278 6.561e-07 0.0001525
21 REGULATION OF CELL DEVELOPMENT 63 836 6.882e-07 0.0001525
22 MOVEMENT OF CELL OR SUBCELLULAR COMPONENT 86 1275 7.365e-07 0.0001558
23 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 112 1805 9.115e-07 0.0001837
24 CHROMATIN ORGANIZATION 53 663 9.476e-07 0.0001837
25 POSITIVE REGULATION OF GENE EXPRESSION 108 1733 1.2e-06 0.0002233
26 DEVELOPMENTAL GROWTH 33 333 1.275e-06 0.0002281
27 CELLULAR RESPONSE TO ENDOGENOUS STIMULUS 71 1008 1.605e-06 0.0002766
28 CARDIOVASCULAR SYSTEM DEVELOPMENT 59 788 1.931e-06 0.0003099
29 CIRCULATORY SYSTEM DEVELOPMENT 59 788 1.931e-06 0.0003099
30 CELL PROJECTION ORGANIZATION 65 902 2.118e-06 0.0003285
31 RESPONSE TO ENDOGENOUS STIMULUS 93 1450 2.215e-06 0.0003325
32 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 70 1004 2.73e-06 0.0003969
33 UROGENITAL SYSTEM DEVELOPMENT 30 299 2.989e-06 0.0004215
34 REGULATION OF EPITHELIAL CELL PROLIFERATION 29 285 3.297e-06 0.0004513
35 REGULATION OF NEURON DIFFERENTIATION 45 554 4.173e-06 0.0005548
36 POSITIVE REGULATION OF MOLECULAR FUNCTION 108 1791 5.426e-06 0.0006967
37 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 76 1142 5.54e-06 0.0006967
38 CHROMOSOME ORGANIZATION 69 1009 6.228e-06 0.0007535
39 REGULATION OF NEURON PROJECTION DEVELOPMENT 36 408 6.316e-06 0.0007535
40 REGULATION OF GTPASE ACTIVITY 51 673 6.964e-06 0.0008101
41 CIRCADIAN RHYTHM 18 137 7.701e-06 0.0008739
42 REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 23 207 8.018e-06 0.0008883
43 TISSUE DEVELOPMENT 94 1518 8.299e-06 0.0008981
44 LOCOMOTORY BEHAVIOR 21 181 1.01e-05 0.001068
45 CIRCADIAN REGULATION OF GENE EXPRESSION 11 57 1.193e-05 0.001207
46 NEURON DIFFERENTIATION 61 874 1.184e-05 0.001207
47 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 115 1977 1.357e-05 0.001344
48 PROTEIN PHOSPHORYLATION 64 944 1.784e-05 0.00173
49 EPITHELIUM DEVELOPMENT 64 945 1.843e-05 0.00175
50 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 99 1656 1.989e-05 0.001851
51 REGULATION OF CELL CYCLE 64 949 2.098e-05 0.001914
52 POSITIVE REGULATION OF CATALYTIC ACTIVITY 92 1518 2.403e-05 0.00215
53 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 64 957 2.708e-05 0.002292
54 REGULATION OF CELLULAR LOCALIZATION 80 1277 2.759e-05 0.002292
55 ORGAN MORPHOGENESIS 58 841 2.743e-05 0.002292
56 CHROMATIN REMODELING 18 150 2.709e-05 0.002292
57 SKELETAL SYSTEM DEVELOPMENT 37 455 2.89e-05 0.002359
58 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 67 1021 3.16e-05 0.002535
59 REGULATION OF DEVELOPMENTAL GROWTH 27 289 3.322e-05 0.002589
60 POSITIVE REGULATION OF HYDROLASE ACTIVITY 61 905 3.338e-05 0.002589
61 REGULATION OF HYDROLASE ACTIVITY 82 1327 3.528e-05 0.002691
62 POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 18 154 3.864e-05 0.002854
63 PHOSPHORYLATION 77 1228 3.814e-05 0.002854
64 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 23 229 4.1e-05 0.00289
65 TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY 39 498 4.094e-05 0.00289
66 REGULATION OF CELLULAR PROTEIN LOCALIZATION 42 552 4.085e-05 0.00289
67 MUSCLE ORGAN DEVELOPMENT 26 277 4.269e-05 0.002964
68 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 42 554 4.437e-05 0.003036
69 COVALENT CHROMATIN MODIFICATION 30 345 4.817e-05 0.003202
70 HEART DEVELOPMENT 37 466 4.804e-05 0.003202
71 NEURON DEVELOPMENT 49 687 5.037e-05 0.003287
72 MUSCLE STRUCTURE DEVELOPMENT 35 432 5.087e-05 0.003287
73 REGULATION OF CELL PROJECTION ORGANIZATION 42 558 5.227e-05 0.003332
74 RHYTHMIC PROCESS 27 298 5.653e-05 0.003555
75 REGULATION OF CELLULAR COMPONENT MOVEMENT 53 771 6.622e-05 0.004054
76 NEURON PROJECTION GUIDANCE 21 205 6.568e-05 0.004054
77 ACTION POTENTIAL 13 94 8.108e-05 0.004899
78 REGULATION OF CYTOPLASMIC TRANSPORT 37 481 9.267e-05 0.005528
79 MUSCLE TISSUE DEVELOPMENT 25 275 9.968e-05 0.005805
80 SKIN EPIDERMIS DEVELOPMENT 11 71 0.0001002 0.005805
81 NEGATIVE REGULATION OF CHROMOSOME ORGANIZATION 13 96 0.0001011 0.005805
82 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 83 1395 0.0001151 0.006533
83 SPLEEN DEVELOPMENT 8 39 0.0001185 0.006643
84 APPENDAGE DEVELOPMENT 18 169 0.0001304 0.007139
85 LIMB DEVELOPMENT 18 169 0.0001304 0.007139
86 REGULATION OF TRANSPORT 102 1804 0.0001321 0.007147
87 NEURON PROJECTION MORPHOGENESIS 32 402 0.0001459 0.007804
88 POSITIVE REGULATION OF DEVELOPMENTAL GROWTH 17 156 0.0001504 0.007954
89 SEX DIFFERENTIATION 24 266 0.0001529 0.007995
90 REGULATION OF CELL DEATH 86 1472 0.0001596 0.008249
91 CELLULAR COMPONENT MORPHOGENESIS 58 900 0.0001744 0.008918
92 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 28 337 0.0001841 0.009311
NumGOOverlapSizeP ValueAdj. P Value
1 NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY 100 1199 7.707e-13 7.159e-10
2 REGULATORY REGION NUCLEIC ACID BINDING 74 818 2.358e-11 1.095e-08
3 TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING 58 588 1.434e-10 4.44e-08
4 ADENYL NUCLEOTIDE BINDING 108 1514 1.109e-09 2.577e-07
5 SEQUENCE SPECIFIC DNA BINDING 80 1037 6.991e-09 1.299e-06
6 CHROMATIN BINDING 44 435 1.196e-08 1.853e-06
7 MACROMOLECULAR COMPLEX BINDING 98 1399 1.813e-08 2.406e-06
8 DOUBLE STRANDED DNA BINDING 63 764 2.785e-08 3.234e-06
9 TRANSCRIPTION COREPRESSOR ACTIVITY 28 221 5.517e-08 5.695e-06
10 RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING 53 629 1.852e-07 1.721e-05
11 RIBONUCLEOTIDE BINDING 117 1860 2.472e-07 2.088e-05
12 KINASE ACTIVITY 64 842 4.148e-07 3.211e-05
13 PROTEIN KINASE ACTIVITY 51 640 1.671e-06 0.0001194
14 CORE PROMOTER PROXIMAL REGION DNA BINDING 35 371 1.91e-06 0.0001268
15 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 67 992 1.275e-05 0.0007896
16 HISTONE DEACETYLASE BINDING 15 105 1.582e-05 0.0009185
17 ENZYME BINDING 103 1737 1.86e-05 0.001016
18 HISTONE BINDING 19 177 7.712e-05 0.00398
19 CORE PROMOTER BINDING 17 152 0.0001093 0.005343
20 PROTEIN TYROSINE KINASE ACTIVITY 18 176 0.0002176 0.009628
21 LIGAND DEPENDENT NUCLEAR RECEPTOR BINDING 6 23 0.0002112 0.009628
NumGOOverlapSizeP ValueAdj. P Value
1 NEURON PROJECTION 68 942 1.148e-06 0.0006706
2 NEURON PART 82 1265 6.268e-06 0.00183

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 MAPK_signaling_pathway_hsa04010 29 295 6.495e-06 0.0002457
2 Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 18 139 9.449e-06 0.0002457
3 Rap1_signaling_pathway_hsa04015 21 206 7.048e-05 0.001222
4 Ras_signaling_pathway_hsa04014 21 232 0.0003698 0.004807
5 Cell_cycle_hsa04110 13 124 0.001252 0.01302
6 TGF_beta_signaling_pathway_hsa04350 10 84 0.00172 0.01491
7 FoxO_signaling_pathway_hsa04068 11 132 0.0156 0.1098
8 HIF_1_signaling_pathway_hsa04066 9 100 0.0174 0.1098
9 ErbB_signaling_pathway_hsa04012 8 85 0.01901 0.1098
10 Phosphatidylinositol_signaling_system_hsa04070 8 99 0.04214 0.2191
11 AMPK_signaling_pathway_hsa04152 9 121 0.05045 0.2199
12 cAMP_signaling_pathway_hsa04024 13 198 0.05102 0.2199
13 Calcium_signaling_pathway_hsa04020 12 182 0.05767 0.2199
14 Gap_junction_hsa04540 7 88 0.05919 0.2199
15 mTOR_signaling_pathway_hsa04150 10 151 0.0766 0.2655
16 Apelin_signaling_pathway_hsa04371 9 137 0.0933 0.2893
17 Focal_adhesion_hsa04510 12 199 0.09671 0.2893
18 ABC_transporters_hsa02010 4 45 0.1009 0.2893
19 PI3K_Akt_signaling_pathway_hsa04151 19 352 0.1057 0.2893
20 Phospholipase_D_signaling_pathway_hsa04072 9 146 0.1246 0.3239
21 Tight_junction_hsa04530 10 170 0.1366 0.3382
22 Adherens_junction_hsa04520 5 72 0.1551 0.3538
23 Hippo_signaling_pathway_hsa04390 9 154 0.1565 0.3538
24 Sphingolipid_signaling_pathway_hsa04071 7 118 0.1859 0.4027
25 VEGF_signaling_pathway_hsa04370 4 59 0.2038 0.424
26 Oocyte_meiosis_hsa04114 7 124 0.2193 0.425
27 Wnt_signaling_pathway_hsa04310 8 146 0.2207 0.425
28 TNF_signaling_pathway_hsa04668 6 108 0.2549 0.4733
29 p53_signaling_pathway_hsa04115 4 68 0.2812 0.5043
30 Regulation_of_actin_cytoskeleton_hsa04810 10 208 0.3079 0.5337
31 Hippo_signaling_pathway_multiple_species_hsa04392 2 29 0.3187 0.5345
32 cGMP_PKG_signaling_pathway_hsa04022 7 163 0.4654 0.7288
33 Ferroptosis_hsa04216 2 40 0.4726 0.7288
34 Mitophagy_animal_hsa04137 3 65 0.4765 0.7288
35 Cellular_senescence_hsa04218 6 160 0.6091 0.9049
36 Cell_adhesion_molecules_.CAMs._hsa04514 5 145 0.6828 0.9863
37 Endocytosis_hsa04144 8 244 0.7523 1
38 ECM_receptor_interaction_hsa04512 2 82 0.8401 1
39 Cytokine_cytokine_receptor_interaction_hsa04060 8 270 0.841 1
40 Phagosome_hsa04145 3 152 0.9424 1
41 Jak_STAT_signaling_pathway_hsa04630 3 162 0.9572 1
42 Autophagy_animal_hsa04140 2 128 0.9644 1
43 Neuroactive_ligand_receptor_interaction_hsa04080 6 278 0.9656 1
44 Apoptosis_hsa04210 2 138 0.9747 1
45 Necroptosis_hsa04217 2 164 0.9898 1

Quest ID: 55707da539abd94125e6e4d997b2330b